Salvat Pharmaceutical Group surpasses €100 million in revenue and boosts EBITDA by 25% after launching its transformation process

/in /by
  • After Jordi Muntañola’s first year as CEO, the organization has accelerated its cultural and organizational transformation process, with a strong focus on strategic areas such as ophthalmology and otorhinolaryngology.
  • The pharmaceutical company has achieved record results driven by growth in both the Pharma and CDMO divisions.
  • In 2025, the company secured strategic projects to continue strengthening its industrial capabilities, positioning itself as a leading manufacturer of sterile Blow-Fill-Seal (BFS) technology in the European market.

Barcelona, March 18, 2026. Grupo Farmacéutico Salvat has presented its financial results for fiscal year 2025, a year marked by the beginning of a strategic transformation aimed at driving profitable growth, professionalization, and a strong commitment to talent.

In 2025, Salvat reached total net revenues of 100.3 million euros, representing a 10.3% increase compared to the previous year. This solid performance was reflected exceptionally in operating profitability: total EBITDA grew by 24.6%, reaching 17.2 million euros.

The pharmaceutical business played a key role in the group’s growth, generating revenues of 93.8 million euros, an increase of 9.4%. The Spanish market remained the main growth engine with 69.8 million euros, while the International division grew by 10%.

The company’s business model also includes top-tier industrial capabilities. In 2025, the contract development and manufacturing division (CDMO) strengthened its position as one of Salvat’s main growth drivers, reaching revenues of 6.59 million euros, a 24.4% increase compared to 2024.

“Salvat has entered a new phase, and it has done so with historic results,” said Jordi Muntañola, CEO of Salvat. “Surpassing 100 million euros in revenue for the first time is a milestone that reflects the strength of our business model and the work of the entire team. We are building a more agile, strategic organization, prepared to compete at the highest international standards.”

Innovation and industrial capabilities

Innovation remains one of Salvat’s strategic pillars. In 2025, the company invested 5 million euros in proprietary R&D—5% of its sales—with the goal of strengthening its technological platforms and developing differentiated therapeutic solutions in ophthalmology and otorhinolaryngology.

During the year, Salvat also reinforced its international expansion with key milestones such as FDA approval of its otic treatments, including clotrimazole, for the United States, as well as authorization of the ciprofloxacin and fluocinolone acetonide combination for China. The company also secured strategic projects to further enhance its industrial capacity and position itself as a European benchmark in sterile manufacturing using Blow-Fill-Seal (BFS) technology at its Pharmaloop plant in Madrid.

Social impact and talent: Commitment to purpose

Salvat’s transformation process has also been reflected in its culture and human capital. The company now has a team of more than 500 employees and, following the appointment of Jordi Muntañola as CEO one year ago, has strengthened its structure with key hires in 2025 to lead strategic functions.

True to its purpose of contributing to a healthier and happier life, the group reinvests part of its profits to support scientific research projects, promote artistic and musical talent, and assist vulnerable communities through the Salvat Foundation.